Skip to content

Prime Medicine PRME Price / book

Price / book at other companies

Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
5.9×-1.7×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
2.4×+1.5×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
2.5×+0.9×
Beam Therapeutics logo
Beam TherapeuticsBEAM
2.1×+0.4×
Regenxbio logo
RegenxbioRGNX
20.5×+19.2×

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Calculated from Prime Medicine’s reported figures.

Based on the most recent quarter.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's price / book?
Prime Medicine (PRME) reported price / book of 8.2× in Q1 2026.
How has Prime Medicine's price / book changed year-over-year?
Prime Medicine's price / book increased by 235.6% year-over-year, from 2.4× to 8.2×.
What is the long-term trend for Prime Medicine's price / book?
Over 3 years (2022 to 2025), Prime Medicine's price / book has grown at a 5.9% compound annual growth rate (CAGR), from 4.4× to 5.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.